Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCN1 | O60741 | 2/20 | 0.47 |
| ▸ | HCN4 | Q9Y3Q4 | 2/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147583 | 0.89 | HCN1 (0.57) | HCN1HCN4TP53 | |
| SCHEMBL20068934 | 0.87 | HCN1 (0.44) | HCN1HCN4RETTP53 | |
| SCHEMBL25503769 | 0.84 | RET (0.44) | RET | |
| SCHEMBL20147562 | 0.83 | RET (0.41) | HCN4P2RX7RET | |
| SCHEMBL20147578 | 0.83 | MT-CO2 (0.46) | P2RX7RET | |
| SCHEMBL20147981 | 0.83 | RET (0.42) | RET | |
| SCHEMBL20147560 | 0.81 | PIN1 (0.46) | HCN1HCN4P2RX7RETTP53 | |
| SCHEMBL20068953 | 0.80 | P2RX7 (0.47) | HCN1HCN4P2RX7MAPT | |
| SCHEMBL20147642 | 0.79 | RET (0.45) | HCN1HCN4RETTP53POLB | |
| SCHEMBL20068929 | 0.78 | MAPT (0.45) | HCN1HCN4P2RX7RETTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | HCN1 3369/4885HCN4 2282/4885P2RX7 1456/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | HCN1 3369/4885HCN4 2282/4885P2RX7 1456/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | HCN1 3369/4885HCN4 2282/4885P2RX7 1456/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | HCN1 3369/4885HCN4 2282/4885P2RX7 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.